Cellectar Biosciences (CLRB) Accumulated Expenses (2010 - 2025)
Cellectar Biosciences (CLRB) posted Accumulated Expenses of $1.1 million for Q4 2025, up 78.4% sequentially from $611000.0 in Q4 2024, and up 78.4% YoY from $611000.0 in Q4 2024.
Cellectar Biosciences (CLRB) Accumulated Expenses (2010 - 2025) Analysis & Trends
Cellectar Biosciences has reported Accumulated Expenses for 9 years, with the latest figure at $1.1 million in Q4 2025.
- Quarterly Accumulated Expenses rose 78.4% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 78.4% YoY) and the FY2025 annual result came in at $1.1 million, up 78.4% from the prior year.
- Accumulated Expenses improved to $1.1 million in Q4 2025 per CLRB's latest filing, from $611000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $2.1 million in Q4 2023 and troughed at $504000.0 in Q4 2021.
- A 5-year average of $1.0 million and a median of $916000.0 in 2022 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Accumulated Expenses jumped 125.87% in 2023, then sank 70.47% in 2024.
- Over 5 years, Accumulated Expenses stood at $504000.0 in 2021, then soared by 81.75% to $916000.0 in 2022, then soared by 125.87% to $2.1 million in 2023, then tumbled by 70.47% to $611000.0 in 2024, then surged by 78.4% to $1.1 million in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $1.1 million, $611000.0, and $2.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cellectar Biosciences | 6.73 Mn | 6.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 611,000.00 |
| Dec 31, 2023 | 2.07 Mn |
| Dec 31, 2022 | 916,000.00 |
| Dec 31, 2021 | 504,000.00 |
| Dec 31, 2020 | 850,000.00 |
| Dec 31, 2019 | 395,000.00 |
| Dec 31, 2018 | 408,000.00 |
| Dec 31, 2010 | 305,049.00 |